Streetbeat News

WGS

GeneDx Holdings Corp.

http://www.genedx.com

Industry

Medical - Healthcare Information Services

GeneDx Holdings Corp. is a patient centered health intelligence company. It engages in transforming healthcare by applying AI and machine learning to multidimensional, longitudinal clinical and genomic data to build dynamic models of human health and defining optimal, individualized health trajectories. The firm, through its Centrellis health intelligence platform, generates a more complete understanding of disease and wellness and provides science-driven solutions to the most pressing medical needs. The company was founded by Eric Schadt in October 2015 and is headquartered in Stamford, CT.

Open

102.68

Mkt cap

2.6B

Volume

1.1M

High

103.56

P/E Ratio

-49.40

52-wk high

115.60

Low

90.26

Div yield

N/A

52-wk low

7.56

GENEDX HOLDINGS (WGS) has been upgraded to a Zacks Rank #1 (Strong Buy), indicating positive sentiment about its earnings prospects, which could lead to a stock price increase.

Portfolio Pulse from

February 21, 2025 | 6:15 pm

Pomerantz Law Firm is investigating claims on behalf of investors of GeneDx Holdings Corp (NASDAQ:WGS). Investors are encouraged to contact the firm for more information.

Portfolio Pulse from

February 21, 2025 | 3:15 pm

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of GeneDx Holdings Corp. shareholders. Investors are encouraged to contact the firm for more information.

Portfolio Pulse from

February 20, 2025 | 3:15 pm

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of GeneDx Holdings Corp. (NASDAQ:WGS) investors. They encourage investors to seek more information and participate in the investigation.

Portfolio Pulse from

February 19, 2025 | 3:15 pm

GeneDx Holdings is recognized for its advanced genome and exome testing capabilities, significantly reducing diagnostic times and improving patient outcomes. The company's integration with EPIC Aura positions it well in the $45 billion genetic testing market, making it a GARP 'Buy'.

Portfolio Pulse from

February 19, 2025 | 2:45 pm

GeneDx Holdings Corp. (NASDAQ:WGS) held its Q4 2024 earnings call on February 18, 2025. Key participants included CEO Katherine Stueland and CFO Kevin Feeley. Analysts from TD Cowen, Craig-Hallum Capital Group, Jefferies, Goldman Sachs, BTIG, and Wells Fargo participated.

Portfolio Pulse from

February 18, 2025 | 4:15 pm

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of GeneDx Holdings Corp. (NASDAQ:WGS) stockholders. Investors are encouraged to inquire about the securities investigation.

Portfolio Pulse from

February 18, 2025 | 3:15 pm

GeneDx Holdings Corp. (WGS) reported Q4 earnings of $0.70 per share, surpassing the Zacks Consensus Estimate of $0.20. This marks a significant improvement from a loss of $0.59 per share a year ago.

Portfolio Pulse from

February 18, 2025 | 1:30 pm

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of GeneDx Holdings Corp. (NASDAQ:WGS) investors. Investors are encouraged to learn more and assist the investigation.

Portfolio Pulse from

February 17, 2025 | 3:15 pm

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of GeneDx Holdings Corp. shareholders. Investors are encouraged to contact the firm for more information.

Portfolio Pulse from

February 16, 2025 | 3:15 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.